Obigen Pharma Inc. (TPEX:7876)

Market Cap	3.88B
Revenue (ttm)	n/a
Net Income	-325.96M
EPS	-3.07
Shares Out	106.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,091
Open	36.35
Previous Close	36.10
Day's Range	35.95 - 36.45
52-Week Range	33.75 - 69.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Obigen Pharma

Obigen Pharma Inc. engages in research, manufacturing, and promotion of biotechnology and novel botulinum toxin. Preparations in Taiwan. Its lead product OBI-858, a 760 kDa novel toxin protein which fermented and purified from clostridium botulinum type A bacteria, which is in Phase II clinical trial. The company was founded in 2020 and is based in Zhubei, Taiwan.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2020
• Employees: 60
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7876

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 9, 2026

Data Sources Report a data error